LATEST UPDATES » Special Issue 1, March 2020 – Coronavirus Outbreak       » Vol 24, No. 03, March 2020 – Modern-Day Nostradamus: Predicting the Peak of COVID-19 in China with Mathematical Modelling       » A remote-controlled smart platform for organ repair       » COVID-19 and its genetic relationship with other coronaviruses       » Shedding Light on COVID-19 Vaccine Development       » AI enables whole-slide imaging for diagnosis of nasal polyps       » East meets West: cancer therapy using acupuncture and electrochemistry      
Vol 24, No. 03, March 2020For e-subscribers (PDF)
Azelis India acquires S. Zhaveri Pharmakem, increasing market presence

Distributor of chemicals and food ingredients, Azelis, announced in February 2020 its 100 percent acquisition of distribution and indent business of S. Zhaveri Pharmakem, an Indian specialty distributor for the pharmaceutical industry.

Active since 2008, Azelis a distributor of specialty chemical and food ingredients to over 50 countries across the globe announced the acquisition of S. Zhaveri Pharmakem’s distribution business.

This will significantly increase Azelis’s presence in the Indian market and provide prominence in the fast-growing Indian pharmaceutical market. The acquisition paves a crucial step for Azelis’ pharmaceutical expansion in the region amid its strong growth trajectory.

S. Zhaveri Pharmakem was previously fully owned by the Javeri family, following this acquisition its employees within the distribution business will be part of Azelis. Upon closing the deal, Mrs Uma Javeri and Ms. Sonali Sheth will provide support the integration and lead the pharmaceutical business of Azelis in India.

”Becoming part of such a reputable and big international player will not only provide continuity and security of our distribution business, but also additional expertise, infrastructure and growth opportunities. All of those are very important to us and we are thrilled about the next phase in our company history. We have known Azelis for a while, we have a great respect for one another, our values and ethos are shared so we are convinced that this was the right move.” Shares Mrs. Uma Javeri. Managing Director, S. Zhaveri Pharmakem.

India is positioned as the third largest pharmaceutical industry in the world by drug volume and one of the faster growing pharma markets, there is strong growth potential. These are attributed to its chemical synthesis capabilities, formulation expertise, increased accessibility and affordability, as well as the market entry to the U.S. and other larger regions.

“Establishing a strong presence in the pharmaceutical market in India is therefore essential for a distributor like Azelis and we are very excited to have found such a good partner, which will serve as a very good platform to further expand our pharma activities in India. S. Zhaveri has an excellent reputation in the market, a unique set of principles and a very knowledgeable team with a strong expertise in excipients.” Explained Mr. Laurent Nataf, CEO and President, Azelis Asia Pacific.

Click here for the complete issue.

news Proteona leads international consortium to develop SARS-CoV-2 neutralizing antibody to help vulnerable immunocompromised individuals
news One more step towards true precision medicine
news Joining Forces to Elevate Asia's Healthcare Industry
news 4th Global Feed Summit draws Feed Producers, Technology Providers, Raw Materials Suppliers to Bangkok for Key Discussions

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy